Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.
The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.
Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...
The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) ...
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...
Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination ...
Pfizer (PFE) announced that the Food and Drug Administration has approved Braftovi in combination with cetuximab and mFOLFOX6 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback